Photo by Towfiqu barbhuiya on Unsplash
The global antimicrobial susceptibility testing market is projected to grow at a 5.1% CAGR and reach approximately USD 5.08 billion by 2030. This creates opportunities for OTC, Consumer Health, diagnostic and women’s health companies offering prevention, early detection and responsible self-care solutions.
Women’s Health Can Benefit from Non-Antibiotic AMR Strategies
UTIs are particularly relevant to Women’s Health because recurrent symptoms can lead to repeated antibiotic exposure. Building on CPC’s previous analysis of Women’s Health and non-antibiotic UTI prevention, the commercial opportunity now goes beyond individual prevention products.
Successful portfolios can combine evidence-supported OTC, Phyto, Food Supplement and Medical Device solutions with clear consumer instructions, scientifically supported claims and defined referral criteria.
This creates a business case for products that reduce unnecessary antibiotic exposure without delaying appropriate medical care.
Non-Antibiotic OTC and Diagnostic Solutions Form a New Care Pathway
High-potential portfolios can combine:
-
Non-antibiotic prevention products: selected OTC, Phyto, Food Supplement and Medical Device solutions for recurrent infection risk.
-
OTC diagnostics: home UTI test strips, connected readers and pharmacy-based screening tools supporting earlier triage.
-
Point-of-care culture: antimicrobial susceptibility testing linked to telehealth, pharmacy or primary-care referral pathways.
-
Symptom-relief products, consumer education and clear escalation criteria for fever, pregnancy, recurrent symptoms or suspected complicated infection.
Figure 1. Non-antibiotic New Care Pathway
The evidence strategy is critical. FDA databases include OTC urinary tests measuring nitrite and leukocyte esterase. However, NICE concludes that rapid UTI point-of-care technologies require stronger evidence before routine adoption. Winning brands will therefore need validated claims, human-factors testing, simple instructions and partnerships connecting self-testing with professional care.
AMR Market Outlook to 2030 and 2040
By 2030, the updated Global Action Plan aims to support achievement of the UN target to reduce bacterial AMR-associated deaths in humans by 10%.
By 2040, integrated prevent-test-refer models are expected to become a standard approach across Women’s Health, pharmacies, digital health platforms and primary care systems. Companies aiming to participate in this developing segment will require a clear international strategy to identify the most attractive markets, regulatory pathways, distribution models and potential local partners.
Chameleon Pharma Consulting Group (CPC) has over 20 years of experience in supporting Pharma, OTC, Medical Devices, Phyto, and Aesthetic Medicine companies. Having established own offices & local hubs across Latin America, Europe, Asia, the US/Canada, the Middle East, and the CEE/CIS regions is another advantage of CPC. With this local network and expertise gained from 300+ international projects and a team of 25 experts we offer our clients:
- Business Development, M&A, and Due Diligence
- Market Entry & Expansion: Systematic product and country analysis, market reports
- Strategic Partnering: Identifying local partners, acquisitions, or setting up own offices
- Regulatory & Registration: for drugs, MD, Derma, Aesthetic Medicine, etc.
- Market Authorization & Compliance: Holding MAs, conducting pharmacovigilance
- Quality & Certification: GMP certification, pre-GMP audits
Contact us today for your individual request at service@chameleon-pharma.com!
